Back to News
Market Impact: 0.42
Merk; Eisai Win FDA Approval For WELIREG-LENVIMA In Advanced Kidney Cancer
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
Merck and Eisai received FDA approval for WELIREG (belzutifan) combined with LENVIMA (lenvatinib) to treat certain adults with previously treated advanced clear-cell renal cell carcinoma. The approval expands the companies' oncology treatment options in the most common form of kidney cancer and could support incremental revenue from the advanced renal-cell-carcinoma market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
MRK0.82
More News
- H.C. Wainwright raises Surrozen stock price target on Wnt pathway validation
- OpenAI rogue agents leaked 53 images from ChatGPT users and reportedly created nearly 1 million links packing encoded bits of info
- Facebook found liable as TikTok settles for $100m over user safety
- What would a US diesel export ban mean for global fuel prices?
- US court rules against Kalshi, says states can regulate prediction markets
- Appeals court rules that states can regulate Kalshi’s sports prediction markets, dealing another legal blow to platforms